RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
-14.76%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.19B
AUM Growth
-$125M
(-9.5%)
Cap. Flow
+$120M
Cap. Flow
% of AUM
10.08%
Top 10 Holdings %
Top 10 Hldgs %
29.09%
Holding
132
New
11
Increased
77
Reduced
4
Closed
5
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$10.9M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$10.4M |
| 3 |
Edwards Lifesciences
EW
|
$6.7M |
| 4 |
Alkermes
ALKS
|
$6.65M |
| 5 |
RDUS
Radius Health, Inc.
RDUS
|
$6.63M |
Top Sells
| 1 |
Idexx Laboratories
IDXX
|
$9.3M |
| 2 |
RLYP
RELYPSA INC COM
RLYP
|
$7.14M |
| 3 |
AbbVie
ABBV
|
$5.18M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
$4.67M |
| 5 |
Travere Therapeutics
TVTX
|
$2.1M |
Sector Composition
| 1 | Healthcare | 77.92% |
| 2 | Financials | 3.87% |
| 3 | Industrials | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Amgen
AMGN
$153B
| $14.1M | 1.18% |
94,000
+13,100
| +16% | +$1.96M |
|
27
Biogen
BIIB
$20.6B
| $13.8M | 1.16% |
53,150
+2,500
| +5% | +$651K |
|
28
Prothena Corp
PRTA
$460M
| $12.7M | 1.06% |
308,000
+60,000
| +24% | +$2.47M |
|
29
Pediatrix Medical
MD
$1.49B
| $12.6M | 1.06% |
195,000
+2,000
| +1% | +$129K |
|
30
Theravance Biopharma
TBPH
$703M
| $12.2M | 1.02% |
650,500
+5,500
| +0.9% | +$103K |
|
31
McKesson
MCK
$85.5B
| $12.2M | 1.02% |
77,500
+5,000
| +7% | +$786K |
|
32
Jazz Pharmaceuticals
JAZZ
$7.86B
| $11.2M | 0.94% |
85,500
+5,200
| +6% | +$679K |
|
|
33
Bristol-Myers Squibb
BMY
$96B
| $10.9M | 0.91% |
+170,000
| New | +$10.9M |
|
|
PRAH
34
DELISTED
PRA Health Sciences, Inc.
PRAH
| $10.8M | 0.91% |
253,000
| – | – |
|
|
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $10.6M | 0.89% |
147,000
+31,000
| +27% | +$2.24M |
|
36
Penumbra
PEN
$11B
| $10.5M | 0.88% |
228,500
+23,500
| +11% | +$1.08M |
|
|
WBA
37
DELISTED
Walgreens Boots Alliance
WBA
| $10.4M | 0.87% |
+123,500
| New | +$10.4M |
|
38
TherapeuticsMD
TXMD
$12.5M
| $10.1M | 0.84% |
31,500
+7,800
| +33% | +$2.5M |
|
|
ANAC
39
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $9.49M | 0.79% |
177,500
+100,500
| +131% | +$5.37M |
|
40
Incyte
INCY
$16.9B
| $9.46M | 0.79% |
130,500
+3,500
| +3% | +$254K |
|
|
ACHN
41
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $9.42M | 0.79% |
1,220,000
+115,000
| +10% | +$888K |
|
42
Galapagos
GLPG
$2.2B
| $8.78M | 0.74% |
210,000
| – | – |
|
43
BioMarin Pharmaceuticals
BMRN
$11.1B
| $8.52M | 0.71% |
103,250
+33,250
| +48% | +$2.74M |
|
44
Ardelyx
ARDX
$1.57B
| $8.24M | 0.69% |
1,060,400
+377,900
| +55% | +$2.94M |
|
|
WMGI
45
DELISTED
Wright Medical Group Inc
WMGI
| $8.13M | 0.68% |
490,000
+34,000
| +7% | +$564K |
|
|
INOV
46
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $7.91M | 0.66% |
427,300
-50,000
| -10% | -$926K |
|
47
Encompass Health
EHC
$12.6B
| $7.83M | 0.66% |
261,456
+16,341
| +7% | +$489K |
|
|
NVTA
48
DELISTED
Invitae Corporation
NVTA
| $7.7M | 0.65% |
752,500
+129,600
| +21% | +$1.33M |
|
|
JUNO
49
DELISTED
Juno Therapeutics, Inc.
JUNO
| $7.5M | 0.63% |
197,001
| – | – |
|
50
Ultragenyx Pharmaceutical
RARE
$3.07B
| $7.5M | 0.63% |
118,500
+13,000
| +12% | +$823K |
|